Signaturefd, LLC Alaunos Therapeutics, Inc. Transaction History

Signaturefd, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	SELL	$0.04 - $0.13 $2 - $6	-50 Reduced 1.41%	3,500 $0
Q4 2022 Jan 27, 2023	SELL	$0.5 - $261.0 $601 - $313,722	-1,202 Reduced 25.29%	3,550 $2,000
Q3 2022 Nov 08, 2022	BUY	$1.04 - $322.5 $1,250 - $387,645	1,202 Added 33.86%	4,752 $8,000
Q1 2022 May 02, 2022	BUY	$0.62 - $1.17 $31 - $58	50 Added 1.43%	3,550 $2,000
Q4 2021 Jan 25, 2022	SELL	$1.09 - $1.89 $18,339 - $31,799	-16,825 Reduced 82.78%	3,500 $4,000
Q3 2021 Oct 28, 2021	BUY	$1.44 - $2.73 $11,524 - $21,848	8,003 Added 64.95%	20,325 $37,000
Q1 2021 Apr 30, 2021	SELL	$2.82 - $5.6 $987 - $1,959	-350 Reduced 2.76%	12,322 $44,000
Q4 2020 Feb 11, 2021	BUY	$2.09 - $3.09 $19,169 - $28,341	9,172 Added 262.06%	12,672 $32,000
Q3 2020 Nov 03, 2020	SELL	$2.39 - $3.43 $776 - $1,114	-325 Reduced 8.5%	3,500 $9,000
Q2 2020 Jul 30, 2020	SELL	$2.2 - $3.71 $2,083 - $3,513	-947 Reduced 19.84%	3,825 $13,000
Q1 2020 Apr 23, 2020	BUY	$1.9 - $4.98 $2,416 - $6,334	1,272 Added 36.34%	4,772 $12,000
Q2 2018 Aug 14, 2018	BUY	$3.02 - $4.94 $10,570 - $17,290	3,500 New	3,500 $11,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

Stay updated on Signaturefd, LLC with notifications on news.